FDA Brief

Warning letters Drugs

FDA warning letter to

Profounda, Inc.

High riskIssued Feb 1, 2023Posted Mar 14, 2023Division of Pharmaceutical Quality Operations II

FDA warns Profounda about manufacturing quality failures for over-the-counter drugs, including process validation, stability, water system, and glycerin testing.

What happened

FDA inspected Profounda's Orlando drug manufacturing facility from August 3 to August 9, 2022, and cited significant violations of Current Good Manufacturing Practice (CGMP), a set of manufacturing quality rules. The letter says Profounda lacked process validation data for OTC products including Rhinase D, lacked stability data to support a five-year expiry, had a purified water system with a dead leg and stagnant water, had inadequate microbiological lab controls, and did not test glycerin for diethylene glycol or ethylene glycol.

What FDA found

  1. Profounda did not have written production and process controls or validation data to show its OTC drug manufacturing processes were in control.

    21 CFR 211.100(a)
  2. Profounda assigned a five-year expiry to Rhinase D without enough stability data, relying on a different product's stability.

    21 CFR 211.166(a)
  3. Profounda's purified water system had a dead leg and was not continuously circulating, allowing stagnant water that could promote biofilms.

    21 CFR 211.63
  4. Profounda's microbiological laboratory controls were inadequate, including no growth promotion testing of media and no Burkholderia cepacia complex testing for non-sterile water-based drugs.

    21 CFR 211.160(b); 21 CFR 211.165(b)
  5. Profounda did not test every glycerin lot for diethylene glycol and ethylene glycol before use, despite the lethal poisoning risk from DEG contamination.

    21 CFR 211.84(a)

What FDA wants

FDA tells Profounda to correct the violations promptly and respond in writing within 15 working days with corrective actions and prevention plans. The letter also requires specific assessments and testing, including retain-sample testing within 60 days and glycerin DEG/EG results within 30 days.

Who should pay attention

  • brands that buy OTC drug products from this contract manufacturer
  • companies using glycerin or propylene glycol in drug products
  • distributors and pharmacies selling Rhinase D or related OTC drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk